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IMPACT OF REDUCED COPAYMENTS ON MEDICATION ADHERENCE: 
DX-RX PAIRINGTM PROGRAM OUTCOMES
Kim YA1, Smithline N2, Serxner S3, Yokoyama G1
1University of California, San Francisco, San Francisco, CA, USA, 2Mercer, San Francisco, CA, 
USA, 3Mercer, Los Angeles, CA, USA
OBJECTIVES: A large retail employer implemented Mercer’s Dx-Rx PairingTM 
program. This program offers reduced copayments on diabetes, coronary artery 
disease, heart failure, and asthma medications with concurrent enrollment in disease 
management. We measured adherence and assessed medical utilization in 771 program 
enrollees (intervention group) and in those eligible but not enrolled (control group, 
n  997). METHODS: Adherence, deﬁned by Proportion of Days Covered (PDC), 
was calculated using incurred prescription drug claims one year before and 6 months 
after implementation of Dx-RxTM. Paired t-test analysis compared the change in adher-
ence pre- vs. post-implementation in both intervention and control groups. We calcu-
lated propensity scores to adjust for selection bias and subsequently used regression 
analysis to compare the change in adherence between groups. RESULTS: The overall 
adherence in the intervention group increased by 7% (p  0.001) after implementation 
of Dx-RxTM, whereas the overall adherence in the controls decreased by 9% (p  
0.001). Adherence improved especially for inhaled steroid use among Dx-RxTM asth-
matics (46%, p  0.011). However, adherence among diabetics to angiotensin-convert-
ing enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) did not 
improve in either the intervention or the control group (2%, p  0.509; 8%, p  
0.002, respectively). Regression analysis concurred that Dx-RxTM enrollees had a 
greater improvement in PDC than the controls (B  0.094, p  0.001). Larger increases 
in both prescription and medical per member per month (PMPM) costs were also seen 
in Dx-RxTM enrollees. CONCLUSIONS: The Dx-RxTM program improved adherence, 
but did not reduce medical costs in this timeframe. Subanalyses revealed areas of the 
program’s success and areas for improvement.
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IMPOVERISHING MEDICINES: A CROSS-COUNTRY COMPARISON OF 
THE AFFORDABILITY OF MEDICINES
Niëns LM
Erasmus University Rotterdam, Rotterdam, The Netherlands
OBJECTIVES: In low- and middle-income countries medicine costs account for a 
substantial part of total health care costs (WHO estimate: 25–70%). In these countries 
many patients pay for medicines out-of-pocket. This study’s aim was to calculate the 
affordability of four essential medicines (salbutamol inhaler (100 mcg/dose), gliben-
clamide (5 mg), atenolol (50 mg) and amoxicillin (250 mg)) for 17 low- and middle-
income countries. METHODS: Previous research expressed affordability of medicines 
in the number of days’ wages of the lowest paid unskilled government worker. Using 
medicine prices from a joint project between Health Action International & WHO, 
and expenditure data and income distributions from the World Bank, this study 
applied a more common measure of affordability of medicines based on impoverish-
ment (i.e., percentage below US$1 or $2 per day after medicine procurement). Afford-
ability is calculated for Originator Brand (OB) and Lowest Priced Generic (LPG) 
medicines in both the public and private sector. RESULTS: OB medicines are less 
affordable than LPG medicines. Impoverishment rates (IRs) between OB and LPG 
medicines vary substantially; 10.8% vs. 4.0% (OB vs. LPG below US$1, public sector 
atenolol, Philippines). IRs of up to 33.6% were found (below US$1, OB private sector 
amoxicillin, Indonesia). IRs in low-income countries are lower than in middle-income 
countries due to high numbers already living below US$1 or $2 per day. We distin-
guish between those being impoverished and those for whom medicines are unafford-
able in the ﬁrst place (i.e. below US$1 or $2 before medicine procurement). In the 
public sector IRs are lower than in the private sector but availability of medicines is 
low. CONCLUSIONS: In low- and middle-income countries medicine prices in rela-
tion to available income are such that obtaining necessary medication will impoverish 
large numbers of people. These results call for action by politicians, policymakers, and 
civil societies.
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ASSESSMENT OF THE INTERNATIONAL NONPROPRIETARY NAMES 
(INN) PRESCRIBING PILOT PROJECT IN SOUTH KOREA
Kim JY, Lee EK
Sook Myung Women’s University, Seoul, South Korea
OBJECTIVES: The pilot project of International Nonproprietary Names (INN) was 
implemented over nine months at the National Medical Center (NMC). This study 
aimed to assess the impact of INN on its prescribing rate and drug cost savings. 
METHODS: National health insurance claims data were used to analyze the extent 
to which INN prescribing was conducted for outpatients at NMC, and to know which 
drugs were dispensed at pharmacies. INN prescribing rates were compared by month, 
type of clinics, patient’s characteristics and drug classiﬁcations. Also, drug cost savings 
were compared with brand name in terms of average cost, the rate of the highest-priced 
drug, and total drug expenditure. RESULTS: INN prescribing rate was 31.76%. The 
rate was higher for non-prescription drugs (30.2%) than for prescription drugs 
(15.92%). The rate increased with the age of patient; it was higher for patients with 
health insurance (33.61%) than those on Medicaid (26.75%); the rate was higher for 
re-visit (33.7%) than the ﬁrst visit (9.94%). Specialties with the highest rate were 
Internal Medicine and Neurology. Average cost of INN prescribing was lower than 
the brand name prescribing before and during pilot project. Total drug expenditure 
was reduced by 3.63% compared to before the pilot project, and by 4.58% compared 
to brand name prescription during pilot project. CONCLUSIONS: In conclusion, 
doctors’ INN prescribing rate was 31.76% and drug cost savings compared to brand 
name prescription was 3.63% and 4.58% respectively, for before and during pilot 
project. To achieve better results, active participation of doctors in INN prescribing 
and dispensing low-priced drug by pharmacists are essential.
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PHARMACEUTICAL CARE IN THE EYES OF THE PATIENT
Pilat-Nalecz K1, Hermanowski T2
1Medical University of Warsaw, Warsaw, Poland, 2Department of Pharmacoeconomics, 
Medical University of Warsaw, Warsaw, Poland
OBJECTIVES: Pharmaceutical care perception study. METHODS: Survey. RESULTS: 
Patients expectations. CONCLUSIONS: Poland is one of the last countries in the 
European Union in terms of the advancement of the system of pharmaceutical care.       
Polish Pharmaceutical Council accepted a programme called the Strategy of the Phar-
maceutical Care in Poland over two years ago. Introducing the pharmaceutical care 
is not obligatory, but more and more frequently it is perceived as an element of the 
long-term strategy of pharmacies development. The survey was conducted in 2009. 
Apart from identiﬁcation of social expectations concerning pharmaceutical care, the 
survey aimed at determining to what extent is the society informed about this process. 
The survey was conducted in a group of 848 responders. In 65% of the cases, the 
patients did not encounter the pharmaceutical care programme and were not informed 
that it is being implemented by the Polish Health Service, 73% of responders were 
interested in taking part in the care process, expecting some beneﬁts. The responders 
expect the following beneﬁts: 29%—ﬁnancial savings, 28%—avoiding drug inter-    
actions, 24%—reduction of quantity of taken preparations, 14%—control to take         
medicines appropriately, 5%—motivation to dose the medicines appropriately The       
biggest problem for the responders was making notes on utilization of medicines in a 
diary (59%). The other expected problems are: informing the pharmacist about the  
course of pharmacotherapy (24%) and the necessity to follow new rules and being 
systematic (17%). The conducted survey shows that patients are interested in taking 
part in the care process and in result they expect notable ﬁnancial beneﬁts and reduc-
tion of the quantity of medicines taken. To implement efﬁciently the care in pharmacies 
and to encourage patients to take part in the programme, it is necessary to prepare a 
message aimed at fulﬁlment of actual expectations and social needs.
HEALTH CARE USE & POLICY STUDIES – Equity and Access
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UN POUR TOUT, TOUT POUR UN? AN EMPIRICAL ANALYSIS OF 
PHARMACEUTICAL COVERAGE DECISIONS IN THREE COUNTRIES
Harris A
Monash University, Clayton, VIC, Australia
OBJECTIVES: National public insurance coverage of drugs is based on evidence of 
comparative effectiveness and cost effectiveness. This study compares the importance 
of these issues across three jurisdictions (Australia, Canada, England and Wales) that 
have been at the forefront of evidence-based coverage internationally. METHODS: 
A retrospective comparative analysis of data on factors that have been inﬂuential in 
pharmaceutical public insurance coverage decision in England and Wales (NICE), 
Australia (PBAC) and Canada (CDR) was conducted. The probability of coverage for 
drugs was compared across jurisdictions by each key factor. Data items on all drugs 
considered for 2004 to 2008 were extracted from publicly available documents on 
coverage decisions in each country. RESULTS: Recommendations varied considerably 
across countries in part because of different processes including the willingness to 
negotiate on price and the associated attitude to market proliferation of drugs with 
similar characteristics. The data suggest that the three agencies make recommendations 
that are consistent with a cost effectiveness framework; although it is clear that these 
committees have other objectives in addition to efﬁciency. This is consistent with 
previous empirical studies that suggest the strength of evidence of the comparative 
effectiveness of the drug as well the budgetary cost to government is also signiﬁcant 
predictors of listing in addition to cost-effectiveness. CONCLUSIONS: NICE, PBAC, 
and CDR continue to face common issues with respect to the quality and strength of 
the experimental evidence in support of a clinically meaningful effect. There are sig-
niﬁcant differences in recommendations across countries in part due to differences in 
interpretation of evidence differences in objectives and associated processes, particu-
larly with respect to price negotiation.
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PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS:  
A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK
Mansour E1, Le Pen C2, Nestrigue C3, Amalric F1
1IMS Health, Puteaux, Ile de France, France, 2Dauphine University, Paris, France, 3IMS Health, 
Puteaux, France
OBJECTIVES: 1) Compare the quality of primary care in France to that in the UK 
through a comparison of the avoidable hospitalization rates in both countries, and 2)          
Shed light on the determinants of the quality of primary care through a comparison 
of practices between the two countries for three Avoidable Hospital Conditions 
(AHC). METHODS: We counted the total number of hospitalizations for 12 AHCs 
deﬁned by Weissman et al. Patient hospitalization records were drawn from the PMSI 
database for France (2006) and the HES database for England (April 2006–May 
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2007). First, we calculated the age-adjusted hospital admission rates for adults 18      
years and older, based on the United Nations Standard Population. Second, we 
adjusted the avoidable hospitalization rates to the prevalence of corresponding condi-
tions. That was possible for three AHCs for which prevalence was documented: 
asthma, hypertension, and diabetes. To compare primary care practices, we tracked 
and followed, patients treated for pneumonia, pyelonephritis and asthma in the IMS 
DiseaseAnalyser® database based on panels of general practitioners in France and the    
UK. RESULTS: The age-adjusted and the prevalence-adjusted avoidable hospitaliza-
tion rates were simultaneously higher by 24% and 67% for the UK compared to 
France. When comparing the primary care practice in both countries for the same 
pathologies, we found that French and British GPs prescribe similarly according to            
therapeutic recommendations. The only difference we could observe was in the access 
to the primary care providers where the French health system organization makes it 
a lot easier to consult a physician and get appropriate primary care. CONCLUSIONS: 
According to the Avoidable Hospitalization indicator, the quality of primary care is 
better in France than in the UK. It allowed avoiding 18.5% of the hospitalizations for 
the 12 AHCs in 2006 which represents almost 117,000 hospitalizations. Could a         
higher quality of primary care reduce hospital expenditures?
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A POLICY FRAMEWORK FOR FUNDING DRUGS FOR RARE DISEASES
Clarke J1, Bell C2, Coyle D3, Stevenson H4, Evans G5, Martin MJ6, Sabharwal M4,  
Gadhok A4, Winquist E6
1Hospital for Sick Children, Toronto, Ontario, Canada, 2Department of Medicine, St. 
Michael’s Hospital, Toronto, ON, Canada, 3University of Ottawa, Ottawa, ON, Canada, 
4Ontario Public Drug Programs, North York, ON, Canada, 5Queen’s University, Kingston, 
ON, Canada, 6University of Western Ontario, London, ON, Canada
OBJECTIVES: For rare diseases it may be impossible to generate data from random-
ized trials to inform health policy decisions within a reasonable timeframe. Enzyme 
replacement therapies for rare diseases due to inherited metabolic enzyme deﬁciency 
provide an example of this dilemma. The Ontario Public Drug Program convened the 
Drugs for Rare Diseases Working Group (DRD WG) to develop a framework for 
assessing these drugs in a fair, transparent, and consistent way. METHODS: The DRD 
WG developed terms of reference expecting that the ideal policy product would be 
transparent, consistent, and address unique aspects of treatment of a speciﬁc rare 
condition while being adaptable to other dissimilar conditions. The perspective was 
that of a public payer addressing requests for funding generated for a speciﬁc drug, 
and included respect for the principles of “accountability for reasonableness” of 
Daniels and Sabin. Based on these principles, a consensus process was developed and 
tested by case study. RESULTS: No existing policy processes for potential adoption 
were identiﬁed, so a 7-step framework was systematically drafted: 1) Conﬁrm condi-
tion is truly “rare”; 2) Understand the disease; 3) Understand potential value of can-
didate drug; 4) Estimate clinical effectiveness of candidate drug; 5) Estimate cost 
implications and generate a funding recommendation; 6) Review evaluation with 
disease experts and stakeholders; and 7) Reassessment. The framework has been tested 
with 2 case studies: idursulfase for mucopolysaccharidosis II and alglucosidase for 
glycogen storage disease II. Estimation of clinical effectiveness was done using decision 
modeling. Funding recommendations for both drugs were generated. CONCLU-
SIONS: This policy framework attempts to address the policy challenges of funding 
drugs for rare diseases by considering available evidence in a thorough and realistic 
manner. It will inevitably require modiﬁcation with experience. This framework will 
be adapted for other drugs in future and may be of value to other policy makers.
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THE USEFULNESS AND CHALLENGES OF PATIENT ACCESS (RISK 
SHARING) SCHEMES IN THE UK
Lucas F1, Easley C1, Jackson G2
1Pope Woodhead and Associates, St Ives, UK, 2Cambridge University, Cambridge,, UK
OBJECTIVES: Patient access schemes for novel medicines are increasingly imple-
mented in the UK, being based on linking payment to result (outcome-based) or 
capping cost per patient (ﬁnance-based). However, little is known about what schemes 
are actually being run, how useful they are perceived to be and what are the challenges 
faced. We investigated these questions. METHODS: During this qualitative survey, 
we held in depth, open-ended discussions with senior NHS/NICE representatives (n  
11), academics and health care consultants (n  6), and senior pharmaceutical industry 
representatives (n  7). The focus was on patient access schemes for new drugs imple-
mented in the UK during 2000-mid 2009. RESULTS: Of the 13 schemes identiﬁed, 
most are in oncology (n  9), and ﬁnance-based (n  8) rather than outcome-based; 
seven are included in positive NICE appraisals. Awareness and implementation of 
these schemes are highly variable, albeit less for NICE-endorsed ones. NHS respon-
dents acknowledged theoretical utility of the schemes in reducing uncertainty about 
value for money and (for local stakeholders) shifting some of budget impact risk 
towards the industry. But they saw important challenges: potentially cumbersome 
administrative burden, lack of capabilities to assess real implementation costs, and 
high uncertainty about whether relevant NHS stakeholders actually obtain the ﬁnan-
cial payback. For industry stakeholders, the schemes were essentially a means to obtain 
NICE approval following initial rejection, while preserving a high UK price (crucial 
in the context for international price referencing). A lesser consideration was the 
potential for competitive advantage through, for example, positive perceptions about 
the product and company. CONCLUSIONS: NHS and industry stakeholders generally 
see patient access schemes as beneﬁcial, at least in principle. This approach will likely 
continue for high cost drugs that would otherwise have a cost/QALY marginally over 
the accepted threshold. Adoption of more schemes will depend upon the future capa-
bility of the NHS to accurately monitor their ﬁnancial beneﬁts and implementation 
costs.
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PERCEPTIONS OF THE SAUDI STUDENTS ATTENDING AMERICAN 
UNIVERSITIES TOWARDS THE NEW SAUDI MANDATORY 
COOPERATIVE HEALTH INSURANCE PROGRAM (MCHIP) 
IMPLEMENTED IN SAUDI ARABIA
Al-Shawairkh AS1, Bradford JB2
1Security Forces Hospital Program, Riyadh, Saudi Arabia, 2Virginia Commonwealth University, 
Ricmond, VA, USA
OBJECTIVES: This study investigates the perceptions of Saudi students attending 
American universities towards a new Mandatory Cooperative Health Insurance 
Program (MCHIP) that was introduced recently in Saudi Arabia. METHODS: This 
was a cross-sectional study. Data were collected using e-survey method including all 
2210 Saudi students based on a list provided by the Saudi Cultural Mission at USA. 
Likert scale was employed to measure the students’ expectations of the MCHIP with 
respect to cost, quality, and access of health care; (1  strongly agree to 5  strongly 
disagree). Logistic regression was used to measure the effects of knowledge (knowledge 
of the MCHIP, knowledge of the American health system, and total knowledge of 
health insurance) and students’ expectations of the MCHIP regarding cost, quality 
and access. The response variable was categorized as binary; high knowledge 91), 
while low knowledge (0). Validity and reliability were done. RESULTS: Survey 
response rate was 40.6%. A total of 55.6% agree that cost will be increased while 
19.4% disagree with mean score of 2.45 (SD  1.13). A total 65.3% agree that quality 
is going to be improved, while 8.3% disagree with mean score of 2.5 (SD  0.99); 
56.3% agree that access will be improved, while 15.7% disagree with mean score 2.45 
(SD  1.04). Odds ratio of high knowledge compared to low knowledge was 2.91(P-
Value  0.001) for cost, 1.61. (P-Value  0.461) for quality, and 2.64 (P-Value  
0.203) for access. CONCLUSIONS: Majority expected MCHIP implementation will 
increase total costs, improve quality, and increase access to health care in Saudi 
Arabia. Total knowledge of health insurance had a signiﬁcant effect on students’ per-
ceptions of cost and a non-signiﬁcant effect on their perceptions of quality and access 
to health care. To promote success, the MCHIP should provide affordable and acces-
sible quality health care to the population, based on developed regulations. Awareness 
campaign should be launched.
PHP34
USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS 
PREFERENCES FOR HEALTH SYSTEM CHARACTERISTICS IN THE 
UNITED KINGDOWM AND AUSTRALIA
Taylor M1, Saxby R1, Scuffham PA2, Whitty JA3
1University of York, York, UK, 2Grifﬁth University, Meadowbrook, QLD, Australia, 3Grifﬁth 
University, Brisbane, Queensland, Australia
OBJECTIVES: Comparisons are often made between the performances of different 
countries’ health care systems. In 2000, the World Health Organisation (WHO) 
attempted to measure the performance of health systems of 191 countries and to create 
league tables of good and bad performers. However, a major assumption of the WHO 
research was that the general public had the same preferences for health care system 
attributes, no matter which country they were based. Our study aims to provide a 
pilot study to evaluate the public health preferences of citizens of the UK and Australia. 
METHODS: Eight attributes were carefully selected to convey information about a 
health care system. These included: life expectancy, infant mortality rates, waiting 
times, degree of choice, direct access to specialist, level of information provided and 
degree of funding from the public. A discrete choice experiment approach was used 
to model to preferences of the individuals. RESULTS: All characteristics affected the 
likelihood a health system would be preferred, with the exception of the additional       
tax contribution levels required to ﬁnance the system. The Australian sample was 
generally willing to forgo a greater number of years of life expectancy for gains related 
to responsiveness; whilst, the UK sample was willing to forgo a greater number of 
years for equity gains. CONCLUSIONS: The preliminary ﬁndings of this pilot study 
suggest some consistency between the health system preferences of two samples 
selected from the UK and Australia. However, they also provide some indication that    
health system exposure may affect the strength of preferences surrounding the attri-
butes that individuals consider to be important for their preferred health system.
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COMPARATIVE ASSESSMENT OF POSITIVE REIMBURSEMENT LISTS 
AND HTA EFFECTIVENESS IN ADRIATIC REGION
Gavrankapetanovic I1, Vitezic D2, Gavrankapetanovic F1, Francetic I3, Bolanca S4
1Clinical Center University of Sarajevo, Sarajevo, Bosnia, 2Pﬁzer Croatia, Zagreb, Croatia, 
3University Hospital Centre Rijeka, Rijeka, Croatia, 4University Hospital Center Zagreb, 
Zagreb, Croatia
OBJECTIVES: The objective of this study was to compare patient access privileges to 
medicinal products through National Healthcare Reimbursement Systems in Adriatic 
region, namely Slovenia, Croatia, Bosnia and Herzegovina and Serbia. Over the past 
years, in developed countries, major advances have been made in methods and applica-
tion of health technology assessment (HTA). With the exception of Slovenia, other 
countries included in our analysis, have only recently initiated some HTA activities. 
The results of this research shall enable active engagement of national decision makers. 
METHODS: This was a simple country to country comparison of reimbursement lists. 
